Literature DB >> 21543581

Quality control guidelines for amphotericin B, Itraconazole, posaconazole, and voriconazole disk diffusion susceptibility tests with nonsupplemented Mueller-Hinton Agar (CLSI M51-A document) for nondermatophyte Filamentous Fungi.

A Espinel-Ingroff1, E Canton, A Fothergill, M Ghannoum, E Johnson, R N Jones, L Ostrosky-Zeichner, W Schell, D L Gibbs, A Wang, J Turnidge.   

Abstract

Although Clinical and Laboratory Standards Institute (CLSI) disk diffusion assay standard conditions are available for susceptibility testing of filamentous fungi (molds) to antifungal agents, quality control (QC) disk diffusion zone diameter ranges have not been established. This multicenter study documented the reproducibility of tests for one isolate each of five molds (Paecilomyces variotii ATCC MYA-3630, Aspergillus fumigatus ATCC MYA-3626, A. flavus ATCC MYA-3631, A. terreus ATCC MYA-3633, and Fusarium verticillioides [moniliforme] ATCC MYA-3629) and Candida krusei ATCC 6258 by the CLSI disk diffusion method (M51-A document). The zone diameter ranges for selected QC isolates were as follows: P. variotii ATCC MYA-3630, amphotericin B (15 to 24 mm), itraconazole (20 to 31 mm), and posaconazole (33 to 43 mm); A. fumigatus ATCC MYA-3626, amphotericin B (18 to 25 mm), itraconazole (11 to 21 mm), posaconazole (28 to 35 mm), and voriconazole (25 to 33 mm); and C. krusei, amphotericin B (18 to 27 mm), itraconazole (18 to 26 mm), posaconazole (28 to 38 mm), and voriconazole (29 to 39 mm). Due to low testing reproducibility, zone diameter ranges were not proposed for the other three molds.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21543581      PMCID: PMC3147863          DOI: 10.1128/JCM.00393-11

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  6 in total

1.  Optimal susceptibility testing conditions for detection of azole resistance in Aspergillus spp.: NCCLS collaborative evaluation. National Committee for Clinical Laboratory Standards.

Authors:  A Espinel-Ingroff; M Bartlett; V Chaturvedi; M Ghannoum; K C Hazen; M A Pfaller; M Rinaldi; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  Statistical methods for establishing quality control ranges for antibacterial agents in Clinical and Laboratory Standards Institute susceptibility testing.

Authors:  John Turnidge; Gerry Bordash
Journal:  Antimicrob Agents Chemother       Date:  2007-04-16       Impact factor: 5.191

3.  Multicenter evaluation of a new disk agar diffusion method for susceptibility testing of filamentous fungi with voriconazole, posaconazole, itraconazole, amphotericin B, and caspofungin.

Authors:  A Espinel-Ingroff; B Arthington-Skaggs; N Iqbal; D Ellis; M A Pfaller; S Messer; M Rinaldi; A Fothergill; D L Gibbs; A Wang
Journal:  J Clin Microbiol       Date:  2007-04-11       Impact factor: 5.948

4.  Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi.

Authors:  A Espinel-Ingroff; M Bartlett; R Bowden; N X Chin; C Cooper; A Fothergill; M R McGinnis; P Menezes; S A Messer; P W Nelson; F C Odds; L Pasarell; J Peter; M A Pfaller; J H Rex; M G Rinaldi; G S Shankland; T J Walsh; I Weitzman
Journal:  J Clin Microbiol       Date:  1997-01       Impact factor: 5.948

5.  Quality control limits for ampicillin, carbenicillin, mezlocillin, and piperacillin disk diffusion susceptibility tests: a collaborative study.

Authors:  T L Gavan; R N Jones; A L Barry; P C Fuchs; E H Gerlach; J M Matsen; L B Reller; C Thornsberry; L D Thrupp
Journal:  J Clin Microbiol       Date:  1981-07       Impact factor: 5.948

6.  Quality control limits for broth microdilution susceptibility tests of ten antifungal agents.

Authors:  A L Barry; M A Pfaller; S D Brown; A Espinel-Ingroff; M A Ghannoum; C Knapp; R P Rennie; J H Rex; M G Rinaldi
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

  6 in total
  5 in total

1.  Unravelling the Molecular Identification and Antifungal Susceptibility Profiles of Aspergillus spp. Isolated from Chronic Pulmonary Aspergillosis Patients in Jakarta, Indonesia: The Emergence of Cryptic Species.

Authors:  Anna Rozaliyani; Asriyani Abdullah; Findra Setianingrum; Wellyzar Sjamsuridzal; Retno Wahyuningsih; Anom Bowolaksono; Ayu Eka Fatril; Robiatul Adawiyah; Mulyati Tugiran; Ridhawati Syam; Heri Wibowo; Chris Kosmidis; David W Denning
Journal:  J Fungi (Basel)       Date:  2022-04-16

Review 2.  Methods for in vitro evaluating antimicrobial activity: A review.

Authors:  Mounyr Balouiri; Moulay Sadiki; Saad Koraichi Ibnsouda
Journal:  J Pharm Anal       Date:  2015-12-02

3.  Lamisil, a potent alternative antifungal drug for otomycosis.

Authors:  A Zarei Mahmoudabadi; Z Seifi; M Gharaghani
Journal:  Curr Med Mycol       Date:  2015-03

4.  Molecular identification and antifungal susceptibility profile of Aspergillus flavus isolates recovered from clinical specimens in Kuwait.

Authors:  Faten Al-Wathiqi; Suhail Ahmad; Ziauddin Khan
Journal:  BMC Infect Dis       Date:  2013-03-06       Impact factor: 3.090

5.  Printing amphotericin B on microneedles using matrix-assisted pulsed laser evaporation.

Authors:  Roger Sachan; Panupong Jaipan; Jennifer Y Zhang; Simone Degan; Detlev Erdmann; Jonathan Tedesco; Lyndsi Vanderwal; Shane J Stafslien; Irina Negut; Anita Visan; Gabriela Dorcioman; Gabriel Socol; Rodica Cristescu; Douglas B Chrisey; Roger J Narayan
Journal:  Int J Bioprint       Date:  2017-07-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.